CAM
LAB icon

ClariVest Asset Management’s Standard BioTools LAB Stock Holding History

ClariVest Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-293,261
Closed -$1.36M – 682
2019
Q3 		$1.36M Sell
293,261
-315,653
-52% -$2.49M 0.03% 310
2019
Q2 		$7.5M Sell
608,914
-4,600
-0.7% -$58.6K 0.17% 127
2019
Q1 		$8.15M Buy
+613,514
New +$6.47M 0.16% 129

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

ClariVest Asset Management's LAB Position: Q4 2019 in Review

ClariVest Asset Management sold out of Standard BioTools (LAB) in Q4 2019, closing a stake of 293,261 shares — an estimated $1.36M sold.

ClariVest Asset Management first reported a position in LAB in Q1 2019 and held it in 3 quarters. The position peaked at $8.15M in Q1 2019. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

  • ClariVest Asset Management reported no remaining Standard BioTools position as of Q4 2019 after selling out during the quarter.
  • ClariVest Asset Management sold 293,261 Standard BioTools shares in Q4 2019, an estimated $1.36M.
  • ClariVest Asset Management first reported a position in Standard BioTools in Q1 2019 and held it in 3 quarters.
  • ClariVest Asset Management's Standard BioTools position peaked at $8.15M in Q1 2019.
  • 99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on ClariVest Asset Management's 13F filing for Q4 2019, filed 12 Feb 2020.